Adenosine A3 receptor agonist reduces early brain injury in subarachnoid haemorrhage

Neuroreport. 2010 Sep 15;21(13):892-6. doi: 10.1097/WNR.0b013e32833dbd13.

Abstract

Inflammation plays an important role in the pathogenesis of early brain injury after subarachnoid haemorrhage. Adenosine A3 receptor (A3R) activation produces anti-inflammatory effects. In this study, the effects of a selective A3R agonist, 2-chloro-N⁶-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (CL-IB-MECA), on early brain injury and inflammatory response after subarachnoid haemorrhage were studied. Our results showed that mortality, neurological impairment and brain oedema were significantly attenuated after the administration of CL-IB-MECA. Moreover, treatment with CL-IB-MECA inhibited microglial activation and reduced the expression of proinflammatory cytokines including tumour necrosis factor-α and interleukin-1β. These data suggest that activation of A3R provides a neuroprotective effect against brain injury after subarachnoid haemorrhage, and that these effects may be associated with the anti-inflammatory properties of A3R.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / analogs & derivatives*
  • Adenosine / therapeutic use
  • Adenosine A3 Receptor Agonists / therapeutic use*
  • Analysis of Variance
  • Animals
  • Brain Injuries / drug therapy*
  • Brain Injuries / etiology
  • Brain Injuries / prevention & control
  • Enzyme-Linked Immunosorbent Assay
  • Fluorescent Antibody Technique
  • Male
  • Rats
  • Rats, Sprague-Dawley
  • Subarachnoid Hemorrhage / complications
  • Subarachnoid Hemorrhage / drug therapy*

Substances

  • Adenosine A3 Receptor Agonists
  • Adenosine
  • 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide